EVIDENCE WATCH
A review and assessment of recent clinical trial data

Renal cancer
Mary MacKenzie, MD, FRCPC
A RANDOMIZED, CONTROLLED, DOUBLE-BLIND PHASE III STUDY (AVOREN ) OF BEVACIZUMAB/ INTERFERON-a2A VS PLACEBO/INTERFERON-a2A AS FIRST-LINE THERAPY IN METASTATIC RENAL CELL CARCINOMA. ASCO 2007, ABSTRACT 3.

SUNITINIB VERSUS INTERFERON-ALFA (IFN-A) AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS. ASCO 2007, ABSTRACT 5024.

RANDOMIZED PHASE II TRIAL OF FIRST-LINE TREATMENT WITH SORAFENIB VERSUS INTERFERON IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: FINAL RESULTS. ASCO 2007, ABSTRACT 5025.

Locally advanced prostate cancer
Lori Wood, MD, MSc, FRCPC
CONCOMITANT AND ADJUVANT ANDROGEN DEPRIVATION (ADT) WITH EXTERNAL BEAM IRRADIATION (RT) FOR LOCALLY ADVANCED PROSTATE CANCER: 6 MONTHS VERSUS 3 YEARS ADT-RESULTS OF THE RANDOMIZED EORTC PHASE III TRIAL 22961. ASCO 2007, ABSTRACT 5014.

Hormone-resistant prostate cancer
Lori Wood, MD, MSc, FRCPC
SATRAPLATIN (S) DEMONSTRATES SIGNIFICANT CLINICAL BENEFITS FOR THE TREATMENT OF PATIENTS WITH HRPC: RESULTS OF A RANDOMIZED PHASE III TRIAL. ASCO 2007, ABSTRACT 5019.

Adjuvant taxanes in high-risk breast cancer
Sunil Verma, MD, MSEd, FRCPC and Danny Robson, MD, FRCPC
PHASE III STUDY OF DOXORUBICIN-CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL OR DOCETAXEL GIVEN EVERY 3 WEEKS OR WEEKLY IN OPERABLE BREAST CANCER: RESULTS OF INTERGROUP TRIAL E1199. ASCO 2007, ABSTRACT 516.

Chemotherapy in metastatic breast cancer
Sunil Verma, MD, MSEd, FRCPC and Danny Robson, MD, FRCPC
A RANDOMIZED TRIAL OF CAPECITABINE (C) GIVEN INTERMITTENTLY (IC) RATHER THAN CONTINUOUSLY (CC) COMPARED TO CLASSICAL CMF AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED BREAST CANCER (ABC). ASCO 2007, ABSTRACT 1031.

PHASE III TRIAL OF IXABEPILONE PLUS CAPECITABINE COMPARED TO CAPECITABINE ALONE IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED OR RESISTANT TO AN ANTHRACYCLINE AND RESISTANT TO TAXANES. ASCO 2007, ABSTRACT 1006.